Gliptin-Associated Bullous Pemphigoid: A Valuable Model of the Mechanism of Breakdown of Immune Tolerance against BP180
- PMID: 30904079
- DOI: 10.1016/j.jid.2018.11.025
Gliptin-Associated Bullous Pemphigoid: A Valuable Model of the Mechanism of Breakdown of Immune Tolerance against BP180
Abstract
The study by Plaquevent et al. strongly supports the recent discovery that the use of gliptins is a risk factor for bullous pemphigoid (BP). However, regarding the phenotype of gliptin-associated BP and the necessity of gliptin withdrawal, clinical data remain scarce. We predict that future studies of gliptin-associated BP will offer valuable information concerning autoimmunity against BP180 and may also shed light on the pathology of autoimmune diseases in general.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
Comment on
-
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population.J Invest Dermatol. 2019 Apr;139(4):835-841. doi: 10.1016/j.jid.2018.10.045. Epub 2018 Dec 10. J Invest Dermatol. 2019. PMID: 30543900
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
